Andrew Galazka
Director/Board Member at MedXCell SA
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vincent Lawton | M | 75 | 15 years | |
| Laurent Zbinden | M | - |
MedXCell SA
 MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | 8 years |
| Gabriel Baertschi | M | 50 |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | - |
| Anh Nguyen | M | - |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | - |
| John McMannis | M | - |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | - |
| Jean-Jacques De Dardel | M | - |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ray Hill | M | 79 | 5 years | |
| Bharatt Chowrira | M | 59 | 2 years | |
| Trevor Thomas | M | - |
University of Cambridge
| 7 years |
| Gregory Winter | M | 73 |
University of Cambridge
| 7 years |
| Chris Maggos | M | 54 | - | |
| Tatiana Pont Carteret | F | 58 | 4 years | |
| John Bailey | M | - |
University of Cambridge
| 3 years |
| Adam C. Baker | M | - |
University of Cambridge
| 5 years |
| Belita S. Ong | F | - |
University of Cambridge
| 4 years |
| Mike Gunn | M | - |
University of Cambridge
| 9 years |
| Werner Henrich | M | 80 | - | |
| Mark Epping-Jordan | M | - | 6 years | |
| Gareth Beynon | M | - |
University of Cambridge
| 6 years |
| Angus Porter | M | 67 |
University of Cambridge
| 4 years |
| Steve Young | M | - |
University of Cambridge
| 7 years |
| Michael John Wilson | M | - |
University of Cambridge
| 8 years |
| Khaled Asad Nasr | M | 66 |
University of Cambridge
| 3 years |
| Mark Wainwright Todd | M | 69 |
University of Cambridge
| 4 years |
| Philip Atkin | M | - |
University of Cambridge
| 4 years |
| Jem Davies | M | - |
University of Cambridge
| 3 years |
| Robert Charles Standing | M | 64 |
University of Cambridge
| 4 years |
| Martin Smith | M | - |
University of Cambridge
| 7 years |
| Laurent Galibert | M | 57 | 4 years | |
| Huan Ping Low | M | 68 |
University of Cambridge
| 4 years |
| Vijay Perapti | F | - |
University of Cambridge
| 4 years |
| Steven Troop | M | - |
University of Cambridge
| 4 years |
| Shoong Tat Cheng | M | 63 |
University of Cambridge
| 4 years |
| Steve M. Hobbs | M | - |
University of Cambridge
| 4 years |
| Andrew Broomhead | M | 63 |
University of Cambridge
| 4 years |
| Andrew Unitt | M | 66 |
University of Cambridge
| 4 years |
| David Waimann | M | - |
University of Cambridge
| 3 years |
| Rakesh Sarna | M | - |
University of Cambridge
| 3 years |
| Nicholas French | M | - |
University of Cambridge
| 1 years |
| Richard Morrissey | M | 68 |
University of Cambridge
| 2 years |
| Najeeb Samie | M | - |
University of Cambridge
| 3 years |
| Duncan Clegg | M | - |
University of Cambridge
| 4 years |
| Geoffrey Hale | M | - |
University of Cambridge
| 3 years |
| Robert Gresham Gray | M | 70 |
University of Cambridge
| 4 years |
| John Ryding | M | - |
University of Cambridge
| 4 years |
| Nigel Keith Anthony Standish Vaz | M | 67 |
University of Cambridge
| 4 years |
| Dame Anne Glover | M | - |
University of Cambridge
| 3 years |
| Yong Boon Yeo | M | 69 |
University of Cambridge
| 4 years |
| Colin David Beckett | M | - |
University of Cambridge
| 1 years |
| Martin Andrew McInroy | M | 69 |
University of Cambridge
| 3 years |
| Mike Schraer | M | - |
University of Cambridge
| 2 years |
| Dennis Mulhaupt | M | - |
University of Cambridge
| 3 years |
| Nai Pong Wai | M | 70 |
University of Cambridge
| 4 years |
| Timothy Clissold | M | 64 |
University of Cambridge
| 4 years |
| Hwee Hua Lim | F | 65 |
University of Cambridge
| 4 years |
| Philip Hanson | M | 67 |
University of Cambridge
| 4 years |
| Thomas Martin Connelly | M | 72 |
University of Cambridge
| 3 years |
| Anne Fabienne Weitsch | M | - |
University of Cambridge
| 3 years |
| Anthony Mark Savill | M | - |
University of Cambridge
| 3 years |
| Gerard Evan | M | - |
University of Cambridge
| 4 years |
| Desmond Radlein | M | 74 |
University of Cambridge
| 3 years |
| Graham Keniston-Cooper | M | - |
University of Cambridge
| 4 years |
| Guilherme Brafman | M | - |
University of Cambridge
| 3 years |
| Jonathan Jones | M | - |
University of Cambridge
| 3 years |
| Beatriz Pessoa de Araujo | F | - |
University of Cambridge
| 4 years |
| Hugh Nineham | M | - |
University of Cambridge
| 3 years |
| Kwok-Kuen Leong | M | 63 |
University of Cambridge
| 4 years |
| Frank Christian Wignall | M | 68 |
University of Cambridge
| 4 years |
| Peter Bazalgette | M | 71 |
University of Cambridge
| 4 years |
| Mehran Nakhjavani | M | - |
University of Cambridge
| 3 years |
| Paul Averback | M | 73 |
University of Cambridge
| 3 years |
| George Martin Luckraft | M | 64 |
University of Cambridge
| 4 years |
| David Turnbull | M | 69 |
University of Cambridge
| 4 years |
| Bennett Yankowitz | M | 68 |
University of Cambridge
| 3 years |
| Dominic Casserley | M | 67 |
University of Cambridge
| 4 years |
| David Dew | M | 69 |
University of Cambridge
| 4 years |
| Charles Baker | M | 66 |
University of Cambridge
| 4 years |
| David Godden | M | - |
University of Cambridge
| 4 years |
| Dario Cossutta | M | 73 |
University of Cambridge
| 1 years |
| Geoffrey Hale | M | - |
University of Cambridge
| 3 years |
| Andrew Tomlinson | M | - |
University of Cambridge
| 4 years |
| Suet-Fern Lee | F | 66 |
University of Cambridge
| 3 years |
| Bella Ann Almeida | F | 68 |
University of Cambridge
| 3 years |
| Francis McCormick | M | 73 |
University of Cambridge
| 3 years |
| Graham May | M | 65 |
University of Cambridge
| 3 years |
| William Gilfillan Lamarque | M | 70 |
University of Cambridge
| 4 years |
| Clive Partridge | M | - |
University of Cambridge
| 4 years |
| Andrew Hewson | M | 65 |
University of Cambridge
| 3 years |
| Tony Alves | M | 62 |
University of Cambridge
| 4 years |
| John David Porter | M | - |
University of Cambridge
| 4 years |
| Paul J. Carter | M | - |
University of Cambridge
| 4 years |
| Mark Francis McAllister | M | 66 |
University of Cambridge
| 1 years |
| Lim Andy | M | 66 |
University of Cambridge
| 4 years |
| Charles E. Forrest | M | - |
University of Cambridge
| 3 years |
| Oleg Nodelman | M | 47 | 3 years | |
| Manu Bhaskaran | M | 66 |
University of Cambridge
| 4 years |
| Peter Jackson | M | 62 |
University of Cambridge
| 4 years |
| Fiona Claire Reynolds | F | 66 |
University of Cambridge
| 4 years |
| Anthony Ian Walker | M | - |
University of Cambridge
| 3 years |
| Richard Greer | M | - |
University of Cambridge
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 86 | 86.00% |
| Switzerland | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Galazka
- Personal Network
